Sam Schulman
Schulman, Sam
Schulman, Sam, 1952-
Schulman, Sam (Hematologist)
VIAF ID: 279670233 (Personal)
Permalink: http://viaf.org/viaf/279670233
Preferred Forms
-
100 0 _ ‡a Sam Schulman
-
-
100 1 _ ‡a Schulman, Sam
-
100 1 _ ‡a Schulman, Sam ‡c (Hematologist)
-
100 1 _ ‡a Schulman, Sam ‡d 1952-
-
100 1 _ ‡a Schulman, Sam ‡d 1952-
-
4xx's: Alternate Name Forms (2)
Works
Title | Sources |
---|---|
Perioperative anticoagulation in patients having implantation of a cardiac pacemaker or defibrillator: a systematic review and practical management guide. |
![]() |
Periprocedural Management of Direct Oral Anticoagulants: Comment on the 2015 American Society of Regional Anesthesia and Pain Medicine Guidelines |
![]() |
Pharmacokinetic properties of two factor VIII concentrates with single and double viral inactivation |
![]() |
Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis |
![]() |
Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research |
![]() |
The plasma concentration of activated protein C appears normal in patients with haemophilia |
![]() |
Platelet-leukocyte aggregation under shear stress: Differential involvement of selectins and integrins |
![]() |
Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. |
![]() |
Postoperative low-molecular-weight heparin bridging is associated with an increase in wound hematoma following surgery for pacemakers and implantable defibrillators |
![]() |
Potential antidotes for reversal of old and new oral anticoagulants |
![]() |
Pregnancy, heparin and osteoporosis |
![]() |
Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized |
![]() |
Prophylaxis of venous thromboembolism in patients with infectious disease |
![]() |
Protein C deficiency and thromboembolism: recurrent mutation at Arg 306 in the protein C gene |
![]() |
Prothromplex in stead of Beriplex P/N as acute antidote against warfarin |
![]() |
Psychosocial self-prognosis in relation to mortality and morbidity in hemophiliacs with HIV infection |
![]() |
Pulmonary hypertension in hemophilia |
![]() |
Quality of oral anticoagulant control and treatment in Sweden. Duration of Anticoagulation (DURAC) Trial Study Group |
![]() |
Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy. |
![]() |
Rapid quantitativeD-dimer to exclude pulmonary embolism: a prospective cohort management study |
![]() |
Real-world variability in dabigatran levels in patients with atrial fibrillation |
![]() |
Recommendations on biosimilar low-molecular-weight heparins |
![]() |
Reduced-dose warfarin or interrupted warfarin with heparin bridging for pacemaker or defibrillator implantation: a randomized trial. |
![]() |
Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban |
![]() |
Respiratory review of 2013: pulmonary thromboembolism |
![]() |
Response to Dr Junqueira |
![]() |
Response to letter regarding article, "Management and outcomes of major bleeding during treatment with dabigatran or warfarin" |
![]() |
Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: A prospective cohort study |
![]() |
Review of pumps for continuous infusion of coagulation factor concentrates: what are the options? |
![]() |
rFVIIa-CI Group |
![]() |
The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism |
![]() |
Rivaroxaban in orthopedic surgery--a change of paradigm? |
![]() |
Role of fibrin sealants in surgical procedures on patients with hemostatic disorders. |
![]() |
Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease |
![]() |
Safety, tolerability and pharmacokinetics of escalating doses of NXY-059 in healthy young and elderly subjects. |
![]() |
Selective D-dimer testing for diagnosis of a first suspected episode of deep venous thrombosis: a randomized trial. |
![]() |
Shorter or longer anticoagulation to prevent recurrent venous thromboembolism: systematic review and meta-analysis |
![]() |
Should vitamin K antagonist therapy be started simultaneously with parenteral anticoagulation: a meta-analysis? |
![]() |
The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism. Duration of Anticoagulation (DURAC) Trial Study Group |
![]() |
Social support and the development of immune function in human immunodeficiency virus infection |
![]() |
Stability of factor VIII concentrates after reconstitution |
![]() |
Studies on the medical treatment of deep vein thrombosis, 1985: |
![]() ![]() ![]() |
Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy |
![]() |
Systematic review of observational studies assessing bleeding risk in patients with atrial fibrillation not using anticoagulants |
![]() |
There is evidence for prolonged low-intensity warfarin therapy after venous thrombosis |
![]() |
Thermography in the diagnosis of DVT |
![]() |
Thrombin generation test in children and adolescents with chronic liver disease |
![]() |
Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy |
![]() |
Thrombophilic polymorphism--a short-term or long-term risk for recurrence? |
![]() |
Thromboprophylaxis in medical patients--why not for all? |
![]() |
Thrombosis in inherited factor VII deficiency |
![]() |
Thrombotic complications after substitution with a FVII concentrate |
![]() |
Tossing a coin or using common sense |
![]() |
Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A. |
![]() |
Transmission of hepatitis C with pasteurised factor VIII. |
![]() |
Transmission of HIV infection to heterosexual partners but not to household contacts of seropositive haemophiliacs |
![]() |
Tratamiento del tromboembolismo venoso agudo con dabigatrán o warfarina y análisis combinado |
![]() |
Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
![]() |
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis |
![]() |
Treatment of bleeding complications in patients on anticoagulant therapy |
![]() |
Treatment of venous thromboembolism with new oral anticoagulants according to patient risk. |
![]() |
Validation of a composite score for clinical severity of hemophilia |
![]() |
Validation of a patient decision aid for choosing between dabigatran and warfarin for atrial fibrillation |
![]() |
Venous thromboembolism in older adults: A community-based study |
![]() |
[Venous thromboembolism, warfarin and cancer--a well-known connection] |
![]() |
Von Willebrand disease: an update in the Aland islands |
![]() |
Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial |
![]() |
Warfarin resumption following anticoagulant-associated intracranial hemorrhage: A systematic review and meta-analysis. |
![]() |
When is it safe to stop for safety? |
![]() |
When the rubber meets the road: adherence and persistence with non-vitamin K antagonist oral anticoagulants and old oral anticoagulants in the real world-a problem or a myth ? |
![]() |
Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III study |
![]() |